Phio Pharmaceuticals Corp. (PHIO)

Over the past six months, Phio Pharmaceuticals Corp.'s stock price has been impacted by several events. In July 2025, the company announced a drug substance development services agreement for PH-762. In November 2025, the stock traded down amidst potential strategic shifts, reporting an operating loss and cash burn. Later in November, the stock rose due to positive trial results for PH-762 after the exercise of warrants. Also in November, INTASYL PH-762 was named "Immunomodulatory Solution of the Year" and the company reported positive Q3 2025 financial results, with the PH-762 trial advancing and warrant inducement financing extending the cash runway. In November, the company announced an upcoming presentation and filed to sell shares of common stock. Overall, the stock price declined by 29.59% from January 10, 2025, to January 8, 2026, and experienced a 50% decrease over the past six months.

Based on historical data, there appears to be some seasonality in the stock performance of Phio Pharmaceuticals Corp. Buying the stock in March has historically shown the highest probability of a positive return, while October has demonstrated the lowest probability of a positive return.

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing immuno-oncology therapeutics, utilizing its INTASYL™ siRNA gene silencing technology to enhance immune cell effectiveness against tumors. The company's pipeline includes PH-762, an INTASYL compound in Phase 1b trials targeting PD-1 for cSCC, melanoma, and Merkel cell carcinoma; PH-894, an INTASYL compound in IND-enabling studies designed to silence BRD4; and RXI-185 and RXI-231, INTASYL compounds for age-related skin disorders targeting MMP-1 and TYR proteins.

Phio Pharmaceuticals Corp. is headquartered in Marlborough, Massachusetts, United States. Clinical trials for PH-762 are conducted across various U.S. sites, including George Washington University, Banner MD Anderson, Centricity Research, and Integrity Research. The company also has an exploratory collaboration with a luxury skin care company with a global presence, indicating potential global reach for cosmeceutical applications.

Phio Pharmaceuticals has experienced events that have positively contributed to its brand reputation, alongside inherent risks. The company's INTASYL siRNA platform was featured in a "National Spotlight" and it announced an exploratory collaboration with a luxury skin care company. The INTASYL PH-762 compound was recognized as the "Immunomodulatory Solution of the Year", and positive clinical trial results have contributed positively to the company's scientific and clinical reputation. Analyst ratings present a mixed picture. The company faces challenges that could impact its reputation and financial outlook, including the risks of failed clinical trials, funding difficulties, dilutive capital raises, and concerns regarding commercial success and delisting.

Phio Pharmaceuticals Corp. has a mixed ownership structure. Institutional investors hold approximately 57.31% of the company's stock, with major shareholders including Vanguard Group Inc. and Geode Capital Management, LLC. Insiders own approximately 0.89% of the stock, with Robert Bitterman owning the most shares, and have bought more stock than they have sold in the past three months. Public and individual investors hold approximately 94.07% of the company's stock.